The Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients with Prior Myocardial Infarction and no History of Stroke or TIA: Results from TRA 2°P-TIMI 50.

CONCLUSIONS: -Vorapaxar reduced cardiovascular death, MI, or stroke in stable patients with a history of prior MI, whether treated concomitantly with a thienopyridine or not. The relative risk of moderate or severe bleeding was similarly increased irrespective of thienopyridine use. Clinical Trial Registration Information-http://www.clinicaltrials.gov. Identifier: NCT00526474. PMID: 26338971 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26338971?dopt=Abstract

Source: Circulation - September 3, 2015 Category: Cardiology Authors: Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA Tags: Circulation Source Type: research